Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

Learn More
Latest News

Evidera Acquires Medimix, Expanding Solutions for Real-World Research

Read the Press Release
Policy Trends Update

CADTH Launches Parallel Scientific Advice Programs with NICE and Health Canada

Read about the recent discussion Evidera's Policy Trends team had with CADTH on new opportunities for scientific advice

Access the Full Interview
White Paper

Can Early Collaboration between Multiple European Stakeholders Increase Access for Patients Living with Rare Diseases?

Learn how integrated regulatory and HTA scientific advice can help rare disease evidence planning to increase access for patients

Read Now
A scientific research and consulting expert from Evidera presents at a conference in Philadelphia, Pennsylvania.
ebook

Insights from the NICE 2019 Annual Conference on Transforming Care

Read our experts' recap of the most important highlights from the conference

Read Now
Current opportunities with Evidera.
Career Opportunities

Join Our Growing Team

We’re looking for smart, creative, dedicated, people to join us in optimizing patient access with evidence of value, effectiveness, and safety

Learn More

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2018 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

Infectious Disease

Antimicrobial Resistance or Delayed Appropriate Therapy—Does One Influence Outcomes More Than the Other among Patients With Serious Infections Due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae?

  • Open Forum Infectious Diseases
  • July 2019
Cardiovascular

Patient-Centered Benefit-Risk Analysis of Transcatheter Aortic Valve Replacement

  • F1000Research
  • July 2019
Gastroenterology

An Economic Evaluation of Tofacitinib for the Treatment of Moderately-to-Severely Active Ulcerative Colitis: Modeling the Cost of Treatment Strategies in the United States

  • Journal of Medical Economics
  • June 2019
Read More About Our Publications
What We Do

What We Do

Real-World Evidence

Obtain real-world evidence of value by extracting data from existing sources, collecting primary data, and conducting hybrid studies.

Patient-Centered Research

Develop and evaluate clinical outcomes assessments to support labeling and promotional claims.

Evidence Synthesis, Modeling & Communication

Provide a truly connected value story, supported by strong evidence

Market Access

Optimize market access with cogent payer insights, expert-informed evidence strategy, and persuasive communication of product value.

Interventional Studies

Provide peri- and post-approval evidence via dedicated global operations and custom-tailored study designs.

Pragmatic Studies

Explore patient-centered outcomes and comparative effectiveness using pragmatic studies with adaptive designs.

Medical Writing

Expert medical writing, including medical information, study documentation, and publications, tailored to the peri- and post-approval environment.
Anuraag Kansal, PhD, Sr. Research Leader & Director, Disease & Trial Simulation, Modeling & Simulation at Evidera

In Our Own Words

Our work simulating Alzheimer’s disease progression allows us to offer clients insight into their trial designs, simulate outcomes of alternative designs, and enable clients to anticipate results and make decisions accordingly.

CUP Case Study
Case Study

Robust Modeling Helped Convince NICE to Reverse Their Decision

Learn how Evidera’s experts helped to improve access to a mCRPC treatment in a country with traditionally conservative reimbursement for these therapies.

Read More
Case Study

Compassionate Use Program: Rapid Drug Delivery to Patients in Need

Learn how Evidera, as part of PPD, created a global program across 38 countries to provide treatment within 24-48 hours to 3,100 patients.

Read More
Careers

Meaningful Work at Every Level

We assess candidates across a variety of scientific and operational functions. From leaders in their fields, to those who are new to the industry. We employ people who have a proactive mind-set when it comes to the work they do and helping the people they work with.

Learn More